Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients

Inclusion Criteria: 1. Living in a nursing home who has taken or intends to take azvudine tablets depending on their condition; 2. Mild/normal subjects who are SARS-CoV-2 RT-RCR positive or antigen-positive; 3. Subjects have at least one or more of the following clinical symptoms of COVID-19 in the 24 hours prior to initial administration, including but not limited to: fever, cough, sore throat, stuffy or runny nose, headache, muscle pain, nausea, vomiting, diarrhea, shortness of breath or difficulty breathing, chills or chills; 4. Volunteer to participate in the experiment and sign the informed consent in person or complete the informed consent over the phone. Exclusion Criteria: 1. Subjects have received antiviral therapy, such as Paxlovid and SARS-CoV-2 monoclonal antibody therapy (except previous treatment for COVID-19 infection) before entering the study; 2. Shortness of breath, RR≥30 times/min or resting state, oxygen saturation of finger when sucking air ≤93%; 3. Mechanical ventilation is required or expected to be urgently required; 4. Severe infections requiring systemic treatment within 14 days prior to initial medication; 5. Use of other antiviral drugs (such as anti-HIV, hepatitis B, and hepatitis C drugs) within 14 days prior to the first medication.